MCI is a borderline condition between normal aging and dementia affecting around 23.4 million subjects across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) in 2007, 37% of whom were suffering from prodromal Alzheimer's disease. MCI-specific annual sales are expected to increase seven-fold from 2007 to $3.3 billion across the seven major markets by 2018.
Scope
Definition and prevalence of MCI and its major sub-types.
Review of the key unmet needs in the treatment of the MCI subtypes as identified by key opinion leaders.
MCI-specific drug sales value and number of treated patients forecasts to 2018 in the US, Japan, and five major European markets.
Pipeline analysis with detailed profiles for key late-stage drugs potentially appropriate for MCI patients.
Highlights
Driven by off-label sales of several products currently in development for Alzheimer's disease, MCI-specific annual sales are expected to increase seven-fold from 2007 to $3.3 billion across the seven major markets by 2018.
Although Datamonitor anticipates growth in the number of treated MCI patients (2.3% in 2007 rising to 4.27% in 2018), the treatment rate will remain hampered by the slow uptake of relatively expensive diagnostic tools and lack of marketing authorization for drugs within the forecast period.
In the long-term, Datamonitor believes that MCI will become a viable indication expansion opportunity for companies marketing dementia drugs. However, the current marketed drugs for Alzheimer's disease are not appropriate, and new drugs for dementia are still a few years from the market.
Reasons to Purchase
Better understand the concept of MCI and its limits in the identification of the syndromes sub-types and the approval of treatments.
Quantify the MCI-specific market to 2018 in the US, Japan, and five major European markets and identify the drivers and resistors in this market.
Understand unmet needs and opportunities in the definition, diagnosis and management of MCI based on key opinion leader comments.
(0 items)
